PathAI Announces PathExplore, an AI-powered Pathology Panel to Unlock Untapped Insights from the Tumor Microenvironment
PathAI’s PathExplore panel will empower oncology drug developers with improved tumor microenvironment spatial characterization from H&E, propelling a new phase of precision medicine
BOSTON — April 4, 2023 —PathAI, a global leader in AI-powered pathology, today announced the launch of PathExplore™, the world’s first structured, standardized and scalable panel of human interpretable features (HIFs) offering unprecedented resolution of the tumor microenvironment (TME) from H&E whole-slide images. Powered by artificial intelligence, PathExplore spatially characterizes the TME with single-cell resolution, giving oncology drug developers the ability to unlock insights to inform the next phase of targeted oncology drug development.
The last decade has seen significant strides in oncology therapeutic development, but challenges remain – many cancer patients do not respond to available treatment, and many aren’t eligible for potentially transformative therapies because of a lack of actionable insight into their disease. Researchers are looking to the tumor microenvironment, one of the most promising areas of oncology research, for answers and insights that will impact patient outcomes.
“PathExplore will enable researchers to identify novel spatial signatures predictive of outcomes,” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. “We’re hopeful that by giving oncology drug developers access to this level of detail and data from routine H&E samples, this next generation of pathology will drive advances in cancer therapy development.”
Current technologies to measure and analyze the TME force researchers to make tradeoffs between resolution and scalability. Now with PathExplore, drug developers will have the ability to analyze the TME with deep resolution using a scalable platform that can be deployed on massive numbers of patient samples. PathExplore produces a panel of more than 600 quantitative HIFs: standardized and reproducible measures of counts, densities, areas and spatial relationships across cell types and tissue regions. PathExplore also generates overlay visualizations of cell types and tissue regions, delivered on PathAI’s AISight™ Translational Research platform.
PathExplore has been trained using over 6.5 million pathologist annotations on 66,000 slides. It is currently available for breast cancer, colorectal cancer, gastric cancer, melanoma, non-small cell lung cancer, pancreatic cancer, prostate cancer, and renal cell carcinoma, with more indications planned to launch later this year, including ovarian and bladder cancers. The standardized, structured quantification of the TME across disease areas will enable reproducible, comparable, and scalable analysis across drug programs.
“PathExplore will shift the research paradigm, bypassing long standing constraints we experience with some of the existing multi-omics modalities and allowing for more open exploration and discovery of relationships that were not identifiable by human analysis alone,” said Mike Montalto, PhD, chief scientific officer at PathAI. “The degree of granularity, speed, efficiency and scale delivers unmatched insights that will change the way we view the tumor microenvironment.”
PathAI’s HIFs have been used in over 15 scientific abstracts, presentations, and publications. To learn more about PathExplore, visit www.PathExplore.com or visit us at booth 315 at the American Association for Cancer Research (AACR) April 14th-19th in Orlando, FL.
 PathExplore is for research use only. Not for use in diagnostic procedures.
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Their AI-powered models are rigorously trained and validated with data from more than 15 million annotations and are used to optimize the analysis of patient samples to improve diagnostic efficiency and accuracy, while also accelerating drug development. PathAI is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN. For more information, please visit www.pathai.com.